European Companies Search Engine

EU funding (€15.8M): Liver Investigation: Testing Marker Utility in Steatohepatitis Hor 31 Oct 2017 EU Research and Innovation programme "Horizon"

Overview

Text

Liver Investigation: Testing Marker Utility in Steatohepatitis

Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. It is currently assessed by liver biopsy, an invasive, costly and risky procedure. The lack of noninvasive biomarkers has hampered patient care and impeded drug development by complicating conduct of clinical trials.The overarching aim of LITMUS is to develop, robustly validate and advance towards regulatory qualification biomarkers that diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage. This will be achieved through a goal-oriented, tri-partite collaboration delivering a definitive and impartial evaluation platform for biomarkers, bringing together: (i) End-users of biomarker technologies (clinicians with expertise in NAFLD and the pharmaceutical industry)? (ii) Independent academics with expertise in the evaluation of medical test/biomarker performance? and (iii) Biomarker researchers and developers (academic or commercial). LITMUS has the demonstrable capability to fulfil the IMI call remit. Built upon foundations laid by the EU-funded FLIP/EPoS projects and long-established, successful scientific collaborations amongst many of Europe’s leading clinical-academic centres, LITMUS is at a unique advantage due to its existing large-scale patient cohorts, bioresources and multi-omics datasets. Consortium members are internationally recognised experts with substantial relevant expertise supporting the program’s clear focus on biomarker identification, validation and accelerating EMA/FDA qualification. Thus, LITMUS is powered to provide clarity on biomarker validity for NAFLD at scale and pace: supporting drug development and the targeting of medical care and limited healthcare resources to those at greatest need.


Funded Companies:

Company name Funding amount
Abbvie Inc. €0.00
Allergan Ltd. €0.00
Antaros Medical AB €231,275
Asociacion Centro de Investigacion CRL en Biociencias Cic Biogune €403,018
Assistance Publique Hopitaux de Paris €323,000
Astrazeneca AB €0.00
Boehringer Ingelheim Internationalgesellschaft mbH €0.00
Bristol-Myers Squibb Company Corp €0.00
Consiglio Nazionale Delle Ricerche €0.00
Echosens €0.00
Eli Lilly and Company Ltd. €0.00
Ellegaard Gottingen Minipigs AS €0.00
Ethniko Kai Kapodistriako Panepistimio Athinon €118,350
European Association FOR THE Studyof THE Liver €61,680
Exalenz Bioscience Ltd. €0.00
Faculdade de Farmácia da Universidade de Lisboa €56,969
Faculdade de Medicina da Universidade de Lisboa €78,488
Fondation Cardiometabolisme Nutrition €621,750
Genfit €0.00
Gilead Sciences Inc. €0.00
Helsingin Yliopisto €202,500
Histoindex PTE Ltd. €0.00
Intercept Pharma Europe Ltd. €0.00
Ixscient Ltd. €344,375
Linkopings Universitet €99,600
Luxembourg Institute OF Health €540,034
Medizinische Universitaet Wien €1,944.86
Nordic Bioscience A/S €1,427,093
Novartis Pharma AG €0.00
Novo Nordisk A/S €0.00
One Way Liver SL €1.00
Orebro University €312,500
Perspectum Ltd. €257,500
Pfizer Ltd. €0.00
Research Triangle Institute €0.00
Resoundant Inc. €0.00
Sanofi-Aventis Deutschland GmbH €0.00
Servicio Andaluz de Salud €601,250
Somalogic Inc. €0.00
Sorbonne Universite €0.00
Stichting Amsterdam UMC €1,180,910
Takeda Development Centre Europe Ltd. €0.00
Takeda Pharmaceuticals International AG €0.00
The Chancellor, Masters and Scholars of the University of Oxford €1,811,250
The Chancellor Masters and Scholars of the University of Cambridge €598,005
The University of Birmingham €61,264
The University of Nottingham €118,115
Universita Cattolica Del Sacro Cuore €80,654
Universita Degli Studi Di Firenze €0.00
Universita Degli Studi Di Milano €80,723
Universita Degli Studi Di Palermo €105,081
Universita Degli Studi Di Torino €365,161
Universitaet Bern €435,000
Universitaetsklinikum Aachen €248,076
Universitaetsklinikum Wuerzburg - Klinikum DER Bayerischen Julius-Maximilians-Universitat €406,206
Universitaetsmedizin DER Johannes Gutenberg-Universitaet Mainz €1,073,015
Universitair Medisch Centrum Utrecht €273,329
Universitair Ziekenhuis Antwerpen €167,100
Universite d'Angers €122,500
University of Newcastle Upon Tyne €2,990,166

Source: https://cordis.europa.eu/project/id/777377

The filing refers to a past date, and does not necessarily reflect the current state.